ArticleAmerican journal of hematology2025

BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study.

Lindsey E Roeker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.